Kaleido Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KLDO research report →
Companykaleido.com
Kaleido Biosciences, Inc. , a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease.
- CEO
- Mark A. Wingertzahn
- IPO
- 2019
- Employees
- 76
- HQ
- Lexington, MA, US
Price Chart
Valuation
- Market Cap
- $4.26K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.20
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -113.59%
- Op Margin
- -7940.85%
- Net Margin
- -8178.26%
- ROE
- -580.57%
- ROIC
- -239.53%
Growth & Income
- Revenue
- $1.10M · 13.23%
- Net Income
- $-90,288,000 · -10.62%
- EPS
- $-2.16 · 11.48%
- Op Income
- $-87,667,000
- FCF YoY
- -19.35%
Performance & Tape
- 52W High
- $0.19
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -1.17
- Avg Volume
- 1.32K
Get TickerSpark's AI analysis on KLDO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 28, 22 | van Hylckama Vlieg Johan | other | 2,087 |
| Feb 28, 22 | Korn Jerald | other | 2,046 |
| Jan 14, 22 | van Hylckama Vlieg Johan | other | 350,000 |
| Jan 14, 22 | Long Alison S | other | 125,000 |
| Jan 14, 22 | Long Alison S | other | 46,800 |
| Jan 14, 22 | Korn Jerald | other | 250,000 |
| Jan 14, 22 | Korn Jerald | other | 45,240 |
| Jan 14, 22 | Duke William E. | other | 125,000 |
| Jan 14, 22 | Duke William E. | other | 44,990 |
| Jan 14, 22 | Menichella Daniel L | other | 250,000 |
Our KLDO Coverage
We haven't published any research on KLDO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KLDO Report →